Stock Events

Stock Events

NanoViricides 

$1.2400
56
-$0.04-3.13% Friday 19:59
-$0.01-0.81%Friday 23:50After hours

Statistics

Day High
1.24
Day Low
1.23
52W High
2.23
52W Low
0.85
Volume
12,790
Avg. Volume
-
Mkt Cap
31.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.2
-0.16
-0.12
-0.08
Expected EPS
-0.1
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-9.47MNet Income

Analyst Ratings

6.00Average Price Target
The highest estimate is 6.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NNVC. It's not an investment recommendation.
Amazon
10
AMZN
NVIDIA
10
NVDA
AMD
9
AMD
Tesla
8
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is a biopharmaceutical company that develops antiviral drugs, directly competing with NanoViricides' focus on developing novel treatments for viral diseases.
Moderna
MRNA
Mkt Cap57.94B
Moderna is known for its mRNA technology used in vaccines, including for viruses, positioning it as a competitor in the viral treatment space.
BioNTech
BNTX
Mkt Cap29.28B
BioNTech, similar to Moderna, works on mRNA-based vaccines and therapies for infectious diseases, competing in the viral treatment market.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals develops antiviral drugs and treatments, including monoclonal antibodies, which are in direct competition with NanoViricides' antiviral therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals engages in the creation of antiviral drugs among other therapies, making it a competitor in the viral disease treatment sector.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie has a portfolio that includes antiviral drugs for diseases like HIV and hepatitis, competing with NanoViricides in the antiviral space.
Pfizer
PFE
Mkt Cap159.99B
Pfizer develops and markets drugs and vaccines for a wide range of infectious diseases, including viral infections, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments for viral infections, competing in the same space as NanoViricides.
Novavax
NVAX
Mkt Cap1.47B
Novavax focuses on developing vaccines for infectious diseases, including viral infections, positioning it as a competitor in the prevention and treatment of viral diseases.
Sarepta Therapeutics
SRPT
Mkt Cap1.98B
Sarepta Therapeutics, while primarily focused on genetic medicine, also explores treatments for infectious diseases, potentially competing in the viral therapy market.

About

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Show more...
CEO
Anil R. Diwan
Employees
7
Country
United States
ISIN
US6300873022
WKN
000A2PSNF

Listings

STU
DE
NV3P.STU
MU
DE
NV3P.MU
F
DE
NV3P.F
XASE
US
NNVC

0 Comments

Share your thoughts

FAQ

What is NanoViricides stock price today?▼
The current price of NNVC is $1.24 USD — it has decreased by -3.13% in the past 24 hours. Watch NanoViricides stock price performance more closely on the chart.
What is NanoViricides stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange NanoViricides stocks are traded under the ticker NNVC.
Is NanoViricides stock price growing?▼
NNVC stock has fallen by -6.77% compared to the previous week, the month change is a -20% fall, over the last year NanoViricides has showed a -10.79% decrease.
What is NanoViricides market cap?▼
Today NanoViricides has the market capitalization of 31.65M
When is the next NanoViricides earnings date?▼
NanoViricides is going to release the next earnings report on September 02, 2026.
What were NanoViricides earnings last quarter?▼
NNVC earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.08 USD resulting in a -18.75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NanoViricides revenue for the last year?▼
NanoViricides revenue for the last year amounts to 0 USD.
What is NanoViricides net income for the last year?▼
NNVC net income for the last year is -9.47M USD.
How many employees does NanoViricides have?▼
As of August 30, 2026, the company has 7 employees.
In which sector is NanoViricides located?▼
NanoViricides operates in the Health & Wellness sector.
When did NanoViricides complete a stock split?▼
The last stock split for NanoViricides was on September 24, 2019 with a ratio of 1:20.
Where is NanoViricides headquartered?▼
NanoViricides is headquartered in SHELTON, United States.